Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Galen has acquired the chemotherapy agent, DaunoXome (daunorubicin citrate liposome injection) for advanced HIV-associated Kaposi's Sarcoma, from Gilead Sciences.
Subscribe to our email newsletter
Galen US will market DaunoXome in the US.
KS is a type of cancer that affects both the skin and organs inside the body, such as the lungs, liver, and digestive tract in patients living with active HIV.
Galen president Mark Scrutton said that they are now able to supply DaunoXome in the US for the treatment of patients with this devastating disease.
"This exciting, new acquisition provides us with the opportunity to offer more widely a much-needed therapy for patients with advanced HIV-associated KS," Scrutton added.